Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 201–300 of 999
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Self-citationCiudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04397-4 · Cited by 26
A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
Shah, N., & Sanyal, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003215 · Cited by 17
Self-citationPradhan, R., Yin, H., Lu, S., Sebastiani, G., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2025) · Diabetes Care · doi:10.2337/dc24-1903 · Cited by 16
Liu, C., Zeng, Q., Hu, T., Huang, Y., Song, Y., Guan, H., Rockey, D. C., Tang, H. C., & Li, S. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.100 · Cited by 15
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Nowak, K., Łupina, K., Romac, A., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251322002 · Cited by 21
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Wong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Li, Y., Sun, W., Liu, H., & Ruan, X. Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101761 · Cited by 22
Grocic, M., Nguyen, M., & Sanyal, A. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70662 · Cited by 18
Self-citationKamrul-Hasan, A. B. M., Mondal, S., Dutta, D., Nagendra, L., Kabir, M. R., & Pappachan, J. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70032 · Cited by 23
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Hepatology International · doi:10.1007/s12072-025-10857-9 · Cited by 12
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Júnior, W. S. D. S., Sposito, A. C., & Godoy‐Matos, A. F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.034 · Cited by 12
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Allen, A. M., Arab, J. P., & Wong, V. W. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00990-5 · Cited by 16
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Chen, L., Rao, Q., Gao, M., Lv, G., & Tacke, F. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0541 · Cited by 15
Liu, L., Xia, Y., Wang, B., & Zhang, Y. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70084 · Cited by 13
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
Kamrul-Hasan, A. B. M., Patra, S., Dutta, D., Nagendra, L., Muntahi-Reza, A., Borozan, S., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.101282 · Cited by 17
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 18
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
Lean MASLD and Cardiovascular Disease: A Review
Lebovics, N., Heering, G., Frishman, W. H., & Lebovics, E. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000893 · Cited by 13
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Shi, Y., Kim, S. U., Yip, T. C., Tsochatzis, E. A., Petta, S., Nakajima, A., Hagström, H., Bugianesi, E., Chan, W., Boursier, J., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.001 · Cited by 16
Self-citationCardioMetabolic medicine: the advent of systems cardiology and the new cardiovascular generalist?
Lüscher, T. F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf368 · Cited by 12
Bril, F., Bolla, P., Huynh, K., & Bobba, S. S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf110 · Cited by 14
Hussein, A., Awashra, A., Rajab, I. M., Bdair, M., Hamdan, D., Nouri, A., Khatib, E., Khatib, G., & Latt, N. L. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70075 · Cited by 13
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Nielsen, S. F. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120551 · Cited by 16
Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
Li, J., Chen, R., Zhang, J., He, J., Wang, Y., & Li, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03114 · Cited by 11
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2025.106119 · Cited by 16
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
Genetic Predisposition to MASLD: Potential for Therapeutic Management
Karapanagiotidi, F., Boutari, C., & Sinakos, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041933 · Cited by 10
Righetti, R., Cinque, F., Volpe, M. T., & Sebastiani, G. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2385487 · Cited by 13
Preventing the progression of cirrhosis to decompensation and death
Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 40
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
Lessons from incretin-based therapy in MASH and obesity
Tilg, H., & Targher, G. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01096-2 · Cited by 10
Costa, E. G., Bitetto, D., Fornasiere, E., Fumolo, E., Ferrarese, A., & Toniutto, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134619 · Cited by 14
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 10
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Wang, Y., Chen, Z., Wei, B., Zhang, R., Zhang, X., & Xu, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-90667-z · Cited by 10
Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
Meral, R., Güler, M. Ç., Kaba, D., Prativadi, J., Frontera, E. D., Foss‐Freitas, M. C., Nachawi, N., Broome, D. T., Lightbourne, M., Brown, R. J., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2408 · Cited by 19
Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
Makam, A. N., Bailey, L. R. J., Anderson, N., Bellitti, K., Skinner, S., & Nguyen, O. K. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01449 · Cited by 10
Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 12
Research and application of medicines for treating liver fibrosis: current status and prospects
Chen, S., Wu, Z., Zhang, J., Lin, Y., Xie, J., Yin, D., & Zhu, Y. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1582258 · Cited by 13
Proteomic signatures reflect effects of semaglutide treatment for MASH
Schattenberg, J. M., Grønbæk, H., Kliers, I., Ladelund, S., Long, M. T., Nygård, S. B., Sanyal, A. J., & Davies, M. J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101521 · Cited by 14
Self-citationStachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Henney, A. E., Riley, D. R. J., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025) · Liver International · doi:10.1111/liv.70367 · Cited by 11
Das, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 10
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Acierno, C., Nevola, R., Barletta, F., Zielińska, K., Rinaldi, L., Sasso, F. C., Conte, C., Adinolfi, L. E., & Caturano, A. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001365 · Cited by 14
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 12
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
Insulin resistance: mechanisms and therapeutic interventions
Yu, L., Qian, J., Li, X., Tian, M., Bai, X., Yang, J., Deng, R., Lu, C., He, X., Lü, A., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00408-5 · Cited by 14
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective
Mărginean, C. M., Pîrșcoveanu, D. F. V., Cazacu, S. M., Popescu, M. S., Mărginean, I. C., Iacob, G. A., & Popescu, M. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15040071 · Cited by 10
Behavioral medicine in the GLP-1 era
Tomiyama, A. J. (2024) · Annals of Behavioral Medicine · doi:10.1093/abm/kaae069 · Cited by 51
Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis
Andersson, A., Loomba, R. S., Beyer, C., Mouchti, S., Vuppalanchi, R., Harisinghani, M. G., Ajaz, S., Dinani, A. M., Banerjee, A., Muthiah, M. D., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.03.003 · Cited by 13
Self-citationFerch, M., Peitsch, I., Kautzky‐Willer, A., Greber‐Platzer, S., Stättermayer, A. F., Krebs, M., & Scherer, T. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf258 · Cited by 8
Messer, E. K., Petroff, D., Schattenberg, J. M., Zeuzem, S., von der Ohe, M., Ludwig, L., Demir, M., Buggisch, P., Stein, K., Serfert, Y., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2592-6109 · Cited by 11
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 11
Hartman, M. L., Loomba, R. S., Lawitz, E., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Tang, Y., Brouwers, B., Bunck, M. C. M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101472 · Cited by 10
Self-citationHashim, M. M. A., Khan, M. A. M., Ashraf, M. U., Mohsin, S., Zahoor, K., Niazi, J., Khan, A., Muzaffar, S., Makhdumi, M., Ibad, O. A., et al. (2025) · Cureus · doi:10.7759/cureus.86963 · Cited by 19
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
Angelopoulos, N., Livadas, S., Androulakis, I., Petkova, V., Rizoulis, A. A., Boniakos, A., Paparodis, R. D., Tzoulis, P., Mentzelopoulou, V., Florakis, D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109181 · Cited by 11
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Self-citationHoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Malhotra et al. demonstrated benefits in obstructive sleep apnea, and Loomba et al. reported histological improvements in meta-bolic-associated steatohepatitis (MASH) [61,62].”
Immunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 9
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Self-citationThe National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 9
Using Second-Generation Anti-Obesity Medications
Schmitz, S. H., & Aronne, L. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0002 · Cited by 11
Ren, T., Eslam, M., & Fan, J. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0558 · Cited by 11
Gonzalez, F. J., & Xia, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.046 · Cited by 8
A Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsPreprint
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A. K., Li, O. D.-A., Ogilvie, S., Keeler, A. B., Tian, G., Koita, O., Shi, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628169 · Cited by 8
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Goldney, J., & Davies, M. J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00977-2 · Cited by 7
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.